HOMEX - Sydney
+++++++++++++++++++++++++
DEAL EXPANDS THE BIOLOGICAL APPLICATIONS OF GRADIFLOW(TM) TECHNOLOGY
Gradipore (ASX: GDP) and Serologicals Corporation (Nasdaq: SERO)
today announced a development agreement for evaluating the
application of Gradipore's Gradiflow(TM) separations technology for
the isolation of plasma proteins intended for use as diagnostic
reagents, culture medium supplements, or for therapeutic indications.
The agreement will generate immediate revenue for Gradipore.
Upon successful completion of the evaluation to the specified
requirements of Serologicals, Gradipore and Serologicals will discuss
a more extensive commercial agreement for the purification and
commercialization of other plasma proteins.
"Mass producing medically-relevant products was the intention for the
Gradiflow system, and we have the highest confidence that this
agreement with Serologicals will clearly demonstrate this," said
Gradipore CEO, Robert E Lieb. "Also of importance is the fact that
this deal expands the diversity of biological applications for the
Gradiflow technology."
"The Gradiflow technology offers an attractive alternative to the
existing technologies of fractionation and chromatography with
potentially higher yields at similar or superior quality," said David
A. Dodd President and CEO of Serologicals Corporation. "Serologicals
is excited to start this collaboration and have access to this
promising platform in its continuous pursuit of the manufacture of
the highest quality biologics."
For information on Gradipore, visit the company's corporate web site
at www.gradipore.com.
ABOUT SEROLOGICALS CORPORATION
Serologicals Corporation, headquartered in Atlanta, Georgia, is a
global provider of biological products and enabling technologies,
which are essential for the research, development and manufacturing
of biologically based life science products. The Company's products
and technologies are used in a wide variety of innovative
applications within the areas of oncology, hematology, immunology,
cardiology and infectious diseases, as well as in the study of
molecular biology. Serologicals has more than 650 employees
worldwide, and its shares are traded on the NASDAQ national stock
market under the symbol SERO.
For information on Serologicals Corporation, visit the company's
corporate web site at www.serologicals.com
For further information, please contact:
GRADIPORE (AUSTRALIA)
Simone Lockwood
+61 2 8977 9000
[email protected]
GRADIPORE (UNITED STATES)
Joanna Barnes
(212) 534-4122
[email protected]
PORTER NOVELLI (AUSTRALIA)
Jonathan Revitt ([email protected])
+ 61 2 9463 7600
SEROLOGICALS CORPORATION
Roland Gerritsen van der Hoop, MD, PhD
Vice President of Global Research and
Development
Chief Scientific Officer
(678) 728-2201
[email protected]
- Forums
- ASX - General
- gradipore new usa j/v
gradipore new usa j/v
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)